Detailed Narrative
Q1 FY27 Financial Performance Overview
GPT Healthcare Limited reported a robust Q1 FY27, with total income increasing by 18.2% year-over-year and Profit After Tax (PAT) surging by 66%. Revenue from operations stood at INR 126.2 crores, yielding an EBITDA of INR 26.2 crores, translating to an EBITDA margin of 20.4%. The PAT for the quarter was INR 12.7 crores, with a PAT margin of 9.9%, reflecting strong operational leverage and a favorable case mix.
Hospital-Specific Operational Highlights
The company's mature hospitals demonstrated healthy performance, with network occupancy at 45.5% and 58.07% across mature facilities. ILS Hospital Salt Lake achieved 62% occupancy (up from 60% YoY) and an ARPOB of INR 45,300, driven by higher-contributing surgeries. ILS Hospitals Dumdum maintained its position as the highest occupied hospital at 65% (up from 60% last year) with an ARPOB of INR 43,041. ILS Hospital Howrah saw a 31% YoY revenue increase and 16% occupancy growth, while ILS Hospital Agartala's ARPOB grew 70% to INR 41,573 despite a temporary occupancy dip due to local elections.
Raipur Hospital Ramp-up and Expansion Plans
The newly commissioned ILS Hospital Raipur improved its bed occupancy to 17% from 7% YoY, though it reported a loss of INR 3 crores in Q1 FY27, which is expected to taper throughout the year. The hospital is expanding its service portfolio, including its first liver transplant operation, and aims for an exit occupancy of around 30% by year-end. Construction for the 155-bed tertiary care hospital in Jamshedpur is on schedule for commissioning in Q4 FY27, with an initial ARPOB target of INR 38,000-40,000 and a breakeven period of approximately 24 months.
Strategic Growth and Asset-Light Model
GPT Healthcare is pursuing a disciplined growth strategy, targeting a network capacity of over 1,000 beds within the next two years through the addition of a seventh hospital. The company emphasizes an asset-light model for new facilities, such as Raipur and Jamshedpur, where developers customize buildings for long-term rent, reducing real estate investment and focusing capital on medical assets. This approach is expected to positively impact ROCE.
Patient Mix, ARPOB Drivers, and Talent Management
The improvement in ARPOB to INR 42,350 is primarily attributed to an incremental change in case mix and a focus on high-end tertiary care services like cardiology, oncology, and neurosciences, rather than tariff increases. The company maintains a strong payer mix with approximately 90% of revenues from cash and insurance patients, strategically avoiding government schemes due to lower ARPOB and payment delays. Doctor and nurse attrition rates are low in Calcutta (6-7%) but slightly higher in Agartala and Raipur (around 10%) due to geographic challenges, addressed through training programs and academic initiatives.
Long-term Financial Vision and International Patient Inflows
Management reiterated its long-term target of achieving around 25% ROE and ROCE, supported by continued investment in clinical excellence and specialized offerings. The company anticipates closing FY27 with an EBITDA margin of around 21% (up from 19% last year), translating to an annual EBITDA of INR 110-115 crores. International patient inflows, particularly from Bangladesh to Agartala, are expected to return to pre-disruption levels within the next six months, aided by policy changes requiring targeted hospital names for visa requests.